Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539198 · ClinicalTrials.gov registry record
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 19
- Enrollment target
NCT03539198: Clinical Trial study, sponsored by Mayo Clinic.
NCT03539198 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03539198 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This study observes the clinical efficacy of combining proton SBRT with PD-1 blockade immunotherapy in both the locoregionally recurrent and metastatic settings.
Interventions
- RADIATION Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)
- RADIATION Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).
- DRUG Nivolumab 3 mg/kg IV q2 weeks
- RADIATION Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2020-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539198
The ClinicalTrials.gov registry entry for NCT03539198 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy) is the first listed.
NCT03539198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539198 about?
NCT03539198 is a clinical study titled "Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer". This study observes the clinical efficacy of combining proton SBRT with PD-1 blockade immunotherapy in both the locoregionally recurrent and metastatic settings.
What is the current status of trial NCT03539198?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2018-07-03. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03539198?
The interventions under investigation include: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy) (RADIATION), Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site). (RADIATION), Nivolumab 3 mg/kg IV q2 weeks (DRUG), Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site). (RADIATION).
Who is sponsoring clinical trial NCT03539198?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.